Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; healthcare products and supplements; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. The company was formerly known as Huakang Biomedical Holdings Company Limited and changed its name to Joyzyme Group Limited in January 2026. Joyzyme Group Limited was founded in 1992 and is based in Tsim Sha Tsui, Hong Kong.
Frequently asked questions
What sector does Huakang Biomedical Holdings Co Ltd (8622) operate in?
Huakang Biomedical Holdings Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Huakang Biomedical Holdings Co Ltd (8622) current stock price?
As of the latest data, Huakang Biomedical Holdings Co Ltd stock price is HK$0.22, with a previous close of HK$0.22. Huakang Biomedical Holdings Co Ltd gained HK$0.00 in the last trading session, representing a 1.38% increase.
What is Huakang Biomedical Holdings Co Ltd (8622) current market capitalization?
Huakang Biomedical Holdings Co Ltd market cap is approximately 113.92 million.
What is Huakang Biomedical Holdings Co Ltd (8622) EBITDA?
Huakang Biomedical Holdings Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -103.09 thousand.
Does Huakang Biomedical Holdings Co Ltd (8622) pay dividends?
No. Huakang Biomedical Holdings Co Ltd does not pay a dividend.
What is Huakang Biomedical Holdings Co Ltd (8622) beta (volatility) score?
Huakang Biomedical Holdings Co Ltd has a beta of 0.807, meaning its volatility is roughly in line with the market.
